Synergy bags an FDA OK for constipation therapy Trulance in the lead up to an sNDA
The FDA has handed Synergy Pharmaceuticals $SGYP an approval for plecanatide, which will now hit the market as Trulance for chronic idiopathic constipation.
The biotech, which has stoked rumors about a potential buyout in the recent past, posted some stellar data from a pair of Phase III clinical trials for CIC and now will see if it can give Ironwood a run for its money in offering a rival to Linzess.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.